Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Incyte reported Q3 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, each up 14% year-over-year, driven by growth across its marketed portfolio. Core growth beyond Jakafi was the highlight: Opzelura net sales rose 36% to $255 million and Hematology/Oncology sales rose 38% to $235 million, while flagship Jakafi grew a slower 4% to $827 million. GAAP results swung to a net loss of $3.86 per share due to a one-time $1.23 billion IPR&D charge from the $1.25 billion Vega Therapeutics acquisition; excluding it, operating income grew 18%.
Key figures
- Revenue
- 1557204000
- Guidance
- FY26 total net sales raised to $5,210-$5,300 million (from $5,130-$5,260 million); Opzelura raised to $1,100-$1,120 million; Hematology and Oncology raised to $890-$910 million; all other categories reaffirmed
- Revenue Yoy
- 14%
- Jakafi yoy
- 4%
- Opzelura yoy
- 36%
- Net sales yoy
- 14%
- Total net sales
- 1316413000
- Jakafi net sales
- 826501000
- Vega iprd charge
- 1230000000
- Opzelura net sales
- 254880000
- Hematology oncology yoy
- 38%
- Hematology oncology net sales
- 235000000
- Cash and marketable securities
- 3854572000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.